Renaissance Technologies (RenTech)'s FDMT Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 578,265 shares of 4D Molecular Therapeutics, Inc. (FDMT) worth $5.38 M, representing 0.01% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in FDMT, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 199,714 shares. Largest reduction occurred in Q3 2022, reducing 190,500 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s 4D Molecular Therapeutics (FDMT) Holding Value Over Time
Track share changes against reported price movement
Quarterly 4D Molecular Therapeutics (FDMT) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +65,365 | Add 12.74% | 578,265 | $9.31 |
| Q4 2025 | +199,714 | Add 63.77% | 512,900 | $7.50 |
| Q3 2025 | +196,633 | Add 168.71% | 313,186 | $8.69 |
| Q2 2025 | +97,000 | Add 496.09% | 116,553 | $3.71 |
| Q1 2025 | +19,553 | New Buy | 19,553 | $3.23 |
| Q2 2024 | -69,833 | Sold Out | 0 | $0.00 |
| Q1 2024 | +69,833 | New Buy | 69,833 | $31.86 |
| Q2 2023 | -13,800 | Sold Out | 0 | $0.00 |
| Q1 2023 | -114,300 | Reduce 89.23% | 13,800 | $0.02 |
| Q4 2022 | +59,000 | Add 85.38% | 128,100 | $0.02 |
| Q3 2022 | -190,500 | Reduce 73.38% | 69,100 | $8.05 |
| Q2 2022 | +190,500 | Add 275.69% | 259,600 | $6.98 |
| Q1 2022 | +24,300 | Add 54.24% | 69,100 | $15.12 |
| Q4 2021 | +44,800 | New Buy | 44,800 | $21.94 |
Renaissance Technologies (RenTech)'s 4D Molecular Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased 4D Molecular Therapeutics, Inc. (FDMT) in Q4 2021, acquiring 44,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held 4D Molecular Therapeutics, Inc. (FDMT) for 14 quarters since Q4 2021.
Renaissance Technologies (RenTech)'s largest addition to 4D Molecular Therapeutics, Inc. (FDMT) was in Q4 2025, adding 512,900 shares worth $3.85 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 578,265 shares of 4D Molecular Therapeutics, Inc. (FDMT), valued at approximately $5.38 M.
As of the Q1 2026 filing, 4D Molecular Therapeutics, Inc. (FDMT) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in 4D Molecular Therapeutics, Inc. (FDMT) was 578,265 shares, as reported at the end of Q1 2026.